BME:ALMPharmaceuticals
Assessing Almirall (BME:ALM) Valuation After Positive Phase 3 Lebrikizumab Paediatric Trial Results
Almirall (BME:ALM) is back in focus after reporting positive top line results from its pivotal Phase 3 ADorable 1 trial of lebrikizumab in children and adolescents with moderate to severe atopic dermatitis.
See our latest analysis for Almirall.
Despite the positive paediatric Phase 3 data and the recent push into China, Almirall’s share price return has softened in the short term. The company has recorded a 14.63% 1 month share price decline and an 11.32% year to date share price decline,...